LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.

Labcorp introduces US FDA approved blood test, Lumipulse pTau-217/Beta Amyloid 42 Ratio for Alzheimer's disease: Burlington, North Carolina Tuesday, August 19, 2025, 14:00 Hrs [IS ...

Prenatal exposure to chlorpyrifos -- mostly attributable to indoor residential spraying for pests, prevalent in inner-city ...

Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based ...

FutureWise Research today announces the upcoming release of its comprehensive report, Alzheimer’s Disease Diagnostic Market – ...

Lumipulse blood test: A significant milestone for Alzheimer’s disease Alzheimer’s disease is a progressive brain disorder and the most common cause of dementia. It leads to memory loss, confusion, ...

Evidence of Lumipulse's efficacy included data from the Global Alzheimer's Platform Foundation's Bio-Hermes-001 study, of which both Ixico and Fujirebio are partners. Ixico was responsible for data ...

It’s called the Lumipulse test, and it looks for key proteins in the blood that are linked to the disease’s early stages. “There are several blood tests out there.

The Lumipulse test has specifically been approved to help diagnose the disease in the clinical setting. Dr. Amanada Smith said that makes it the first and only test with that advantage.

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary ...